Program
CKD-508
A development code. Also written as “CKD-508 Tablet” and “CKD-508 Capsule”.
Its studies are led by Chong Kun Dang Pharmaceutical.
Furthest: phase 1, since Jul 22, 20203 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | 30 open or running | phase 1since Jul 22, 2020 | Jul 22, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04488900 · 88 enrolled · United Kingdom
- Dec 2, 2024Phase 1 study in Healthy SubjectsNCT06727396 · 44 enrolled · United States
- May 9, 2025Phase 1 study in HealthyNCT06979973 · 24 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06979973Healthy · United States | 1 | Completed | Aug 17, 2025 | 24 |
| NCT06727396Healthy Subjects · United States | 1 | Completed | Jun 5, 2025 | 44 |
| NCT04488900Healthy Subjects · United Kingdom | 1 | Completed | Jul 2, 2023 | 88 |
How it is read
Names in the registry
- “CKD-508 Tablet”, 3 entries
- “CKD-508 Capsule”, 1 entry
Codes read as this program: CKD508.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.